Stock Market Reviews

MBX (MBX Biosciences, Inc.) News

Get the latest news, insights, and market updates on MBX (MBX Biosciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
  Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross proceeds $391.7 million in cash, cash equivalents and marketable securities as of September 30, 2025; expected to support operations into 2029 Updated 2026 corporate milestones include clinical data for three Precision Endocrine Peptide™ (PEP) programs and initiation of a Phase 3 trial in HP CARMEL,
  Nov 6, 2025 - $MBX
• DraftKings, Flutter downgraded: Wall Street's top analyst calls
  DraftKings, Flutter downgraded: Wall Street's top analyst calls
  Nov 4, 2025 - $MBX
• Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet
  The mean of analysts' price targets for MBX Biosciences, Inc. (MBX) points to a 228.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Oct 29, 2025 - $MBX
• 8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Oct 10, 2025 - $MBX
• Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High?
  The average of price targets set by Wall Street analysts indicates a potential upside of 280.1% in MBX Biosciences, Inc. (MBX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  Oct 9, 2025 - $MBX
• MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
  CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, MD, Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30. Stifel 2025 Virt
  Sep 29, 2025 - $MBX
• MBX Biosciences Announces Pricing of Upsized Public Offering
  CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its upsized public offering of 11,108,055 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducting underwriting disc
  Sep 25, 2025 - $MBX
• MBX Biosciences (MBX) Is Up 84.0% After Positive Phase 2 Results for Canvuparatide - Has The Bull Case Changed?
  On September 22, 2025, MBX Biosciences announced positive topline results from its Phase 2 Avail trial, with once-weekly canvuparatide achieving the primary endpoint with statistical significance and a high responder rate at 6 months in adults with chronic hypoparathyroidism. An impressive 94% of patients who completed the study chose to enter the open-label extension, highlighting ongoing patient engagement and interest in the therapy’s long-term potential. We'll explore how the advancement...
  Sep 23, 2025 - $MBX
• Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet
  The mean of analysts' price targets for MBX Biosciences, Inc. (MBX) points to an 88.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Sep 23, 2025 - $MBX
• MBX to advance hypoparathyroidism drug to Phase III trial
  The study drug also showed positive results in the six-month open-label extension (OLE) trial (NCT06531941).
  Sep 23, 2025 - $MBX